Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
NF-kappaB Pathway Inhibition Targeted Anti-Inflammatory Control KPV provides potent anti-inflammatory effects through direct inhibition of nuclear factor-kappa B (NF-kappaB), distinguishing KLOW from GLOW through enhanced inflammation control[3]: Competitive blocking of importin-alpha3 interaction with NF-kappaB p65/RelA subunit Prevention of NF-kappaB nuclear translocation in activated cells Inhibition of pro-inflammatory gene transcription Reduction of cytokine production including TNF-alpha, IL-1beta, and IL-6 PepT1-mediated cellular uptake enabling intracellular anti-inflammatory action This mechanism operates at nanomolar concentrations and works through a melanocortin receptor-independent pathway, providing inflammation control without hormonal side effects while complementing the other components regenerative actions
However, clinical trials such as STEP-4 demonstrate that weight regain typically occurs after discontinuation of therapy
Most side effects resolve within 2448 hours of discontinuation
The protocol is easy to follow and suitable for clinicians and researchers with a basic understanding of chemistry and bioimaging techniques
US$ 23.24
US$ 23.03
US$ 29.81
US$ 21.83
